Literature DB >> 9200411

Lysyl oxidase expression and collagen cross-linking during chronic adriamycin nephropathy.

A Di Donato1, G M Ghiggeri, M Di Duca, E Jivotenko, R Acinni, J Campolo, F Ginevri, R Gusmano.   

Abstract

Collagen cross-linking induced by lysyl oxidase has been implicated in liver and lung fibrosis. To define the role of this process in kidney fibrosis, we investigated the renal expression of lysyl oxidase and the content in collagen cross-links at various stages of chronic Adriamycin nephropathy in Sprague-Dawley rats. Lysyl oxidase expression was determined by RT-PCR; collagen pyridinium residues, indicating lysyl oxidase induced cross-links, were evaluated by HPLC. These parameters followed a synergic albeit asynchronous outcome: (a) lysyl oxidase mRNA levels in total kidney, glomeruli and medulla from Adriamycin-treated rats increased up to 3 times compared to controls between week 8 and 12, then returning within the normal range; (b) the pyridinium residue content did not show any significant difference between Adriamycin-treated and control rats, until diffuse interstitial fibrosis developed (16 weeks), showing at this time a 2- to 3-fold increment. Lysyl oxidase was expressed by several renal cell lines and in tubular-epithelial cells it was up-regulated in vitro by TGF beta-1, a recognized fibrogenetic factor in Adriamycin nephropathy. Our observations demonstrated that an increased expression of lysyl oxidase in the kidney precedes the development of diffuse fibrotic lesions and that, at this stage, collagenic structures contain highly cross-linked components, the final product of lysyl oxidase activity. The evidence of lysyl oxidase up-regulation in tubular epithelial cells by the same factor implicated in Adriamycin toxicity in the kidney suggests a common pathogenetic mechanism. Collagen cross-link formation by lysyl oxidase may be implicated in the pathogenesis of irreversible, fibrotic renal lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200411     DOI: 10.1159/000190168

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  16 in total

Review 1.  The myofibroblast matrix: implications for tissue repair and fibrosis.

Authors:  Franco Klingberg; Boris Hinz; Eric S White
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

2.  Transforming growth factor-beta1 mediated up-regulation of lysyl oxidase in the kidneys of hereditary nephrotic mouse with chronic renal fibrosis.

Authors:  Yasufumi Goto; Kozue Uchio-Yamada; Sayuri Anan; Yoshie Yamamoto; Atsuo Ogura; Noboru Manabe
Journal:  Virchows Arch       Date:  2005-08-05       Impact factor: 4.064

3.  Lysyl Oxidase-like-2 Cross-links Collagen IV of Glomerular Basement Membrane.

Authors:  Carolina Añazco; Alberto J López-Jiménez; Mohamed Rafi; Lorenzo Vega-Montoto; Ming-Zhi Zhang; Billy G Hudson; Roberto M Vanacore
Journal:  J Biol Chem       Date:  2016-10-21       Impact factor: 5.157

4.  Comparative immunocytochemical localization of lysyl oxidase (LOX) and the lysyl oxidase-like (LOXL) proteins: changes in the expression of LOXL during development and growth of mouse tissues.

Authors:  Kimiko Hayashi; Keith S K Fong; Frederic Mercier; Charles D Boyd; Katalin Csiszar; Masando Hayashi
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

5.  Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.

Authors:  M R Allen; C L Newman; N Chen; M Granke; J S Nyman; S M Moe
Journal:  Osteoporos Int       Date:  2014-12-03       Impact factor: 4.507

6.  Adventitial fibroblast abormality in thoracic aortic aneurysms and aortic dissections.

Authors:  Jong Hui Suh; Jeong-Seob Yoon; Hwan Wook Kim; Keon Hyon Jo
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-12-07

7.  The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

Authors:  Franco Conforti; Elizabeth R Davies; Claire J Calderwood; Thomas H Thatcher; Mark G Jones; David E Smart; Sumeet Mahajan; Aiman Alzetani; Tom Havelock; Toby M Maher; Philip L Molyneaux; Andrew J Thorley; Teresa D Tetley; Jane A Warner; Graham Packham; A Ganesan; Paul J Skipp; Benjamin J Marshall; Luca Richeldi; Patricia J Sime; Katherine M A O'Reilly; Donna E Davies
Journal:  Oncotarget       Date:  2017-07-25

8.  Urinary collagen degradation products as early markers of progressive renal fibrosis.

Authors:  Ryanne S Hijmans; Daniel Guldager Kring Rasmussen; Saleh Yazdani; Gerjan Navis; Harry van Goor; Morten Asser Karsdal; Federica Genovese; Jacob van den Born
Journal:  J Transl Med       Date:  2017-03-20       Impact factor: 5.531

9.  Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.

Authors:  Zhi-feng Zhu; Li-juan Chen; Rong Lu; Jing Jia; Yu Liang; Qiong Xu; Chun-lei Zhou; Li Wang; Song Wang; Zhi Yao
Journal:  BMC Cancer       Date:  2008-11-25       Impact factor: 4.430

10.  Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue.

Authors:  Katerina K Papachroni; Christina Piperi; Georgia Levidou; Penelope Korkolopoulou; Leszek Pawelczyk; Evanthia Diamanti-Kandarakis; Athanasios G Papavassiliou
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.